CN108939139B - 一种具有高效抗炎止血功能医用胶的制备方法 - Google Patents
一种具有高效抗炎止血功能医用胶的制备方法 Download PDFInfo
- Publication number
- CN108939139B CN108939139B CN201810881120.5A CN201810881120A CN108939139B CN 108939139 B CN108939139 B CN 108939139B CN 201810881120 A CN201810881120 A CN 201810881120A CN 108939139 B CN108939139 B CN 108939139B
- Authority
- CN
- China
- Prior art keywords
- parts
- inflammatory
- extract
- hemostatic
- efficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 116
- 230000006870 function Effects 0.000 title claims abstract description 50
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 48
- 239000000853 adhesive Substances 0.000 title claims abstract description 47
- 230000001194 anti-hemostatic effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 89
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 52
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 46
- 230000002439 hemostatic effect Effects 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 23
- 229960000458 allantoin Drugs 0.000 claims abstract description 23
- 239000002131 composite material Substances 0.000 claims abstract description 20
- 229920001651 Cyanoacrylate Polymers 0.000 claims abstract description 19
- 241000209140 Triticum Species 0.000 claims abstract description 18
- 235000021307 Triticum Nutrition 0.000 claims abstract description 18
- 239000003381 stabilizer Substances 0.000 claims abstract description 18
- 229920002689 polyvinyl acetate Polymers 0.000 claims abstract description 14
- 239000008223 sterile water Substances 0.000 claims abstract description 14
- 239000011118 polyvinyl acetate Substances 0.000 claims abstract description 12
- 239000012190 activator Substances 0.000 claims abstract description 8
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019198 oils Nutrition 0.000 claims description 51
- 240000002853 Nelumbo nucifera Species 0.000 claims description 27
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 27
- 239000002024 ethyl acetate extract Substances 0.000 claims description 26
- 241000382353 Pupa Species 0.000 claims description 25
- 244000248162 Xanthoceras sorbifolium Species 0.000 claims description 25
- 235000009240 Xanthoceras sorbifolium Nutrition 0.000 claims description 25
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 25
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 23
- 229920002101 Chitin Polymers 0.000 claims description 22
- 239000003610 charcoal Substances 0.000 claims description 19
- -1 n-octyl Chemical group 0.000 claims description 19
- 230000023597 hemostasis Effects 0.000 claims description 18
- 240000006079 Schisandra chinensis Species 0.000 claims description 17
- 241001211852 Geranium strictipes Species 0.000 claims description 15
- 241000301146 Dendrolimus houi Species 0.000 claims description 14
- 241000172774 Ranunculus ternatus Species 0.000 claims description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 14
- 244000046101 Sophora japonica Species 0.000 claims description 14
- 235000010586 Sophora japonica Nutrition 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 13
- 239000001913 cellulose Substances 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 244000298697 Actinidia deliciosa Species 0.000 claims description 11
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 11
- 241000130781 Arnebia Species 0.000 claims description 11
- 241000208688 Eucommia Species 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000000469 ethanolic extract Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 8
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims description 8
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims description 6
- 241000218206 Ranunculus Species 0.000 claims description 6
- 241000219784 Sophora Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 240000004064 Poterium sanguisorba Species 0.000 claims 1
- 244000081426 Ranunculus ficaria Species 0.000 claims 1
- 239000003921 oil Substances 0.000 description 44
- 230000000694 effects Effects 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 206010061218 Inflammation Diseases 0.000 description 26
- 230000004054 inflammatory process Effects 0.000 description 22
- 206010052428 Wound Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 241000130784 Arnebia euchroma Species 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000000740 bleeding effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000002791 soaking Methods 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 10
- 241001300674 Plukenetia volubilis Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 230000023555 blood coagulation Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229960000304 folic acid Drugs 0.000 description 10
- 235000019152 folic acid Nutrition 0.000 description 10
- 239000011724 folic acid Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241000823550 Ranunculus japonicus Species 0.000 description 8
- 241001530126 Scrophularia Species 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000003292 glue Substances 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 244000173853 Sanguisorba officinalis Species 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241001631712 Dendrolimus pini Species 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000581682 Sanguisorba Species 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002366 mineral element Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 2
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 240000006432 Carica papaya Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 2
- 241000209477 Nymphaeaceae Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000002328 demineralizing effect Effects 0.000 description 2
- 230000003544 deproteinization Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000214 effect on organisms Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 108010093305 exopolygalacturonase Proteins 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 244000237330 gutta percha tree Species 0.000 description 2
- 239000013003 healing agent Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- WOFTVESNUIDLHD-UHFFFAOYSA-N (2,4-dioxoimidazolidin-1-yl)urea Chemical compound NC(=O)NN1CC(=O)NC1=O WOFTVESNUIDLHD-UHFFFAOYSA-N 0.000 description 1
- PRZFUMHWRKSAGP-UHFFFAOYSA-N (3-oxoaziridin-2-yl)urea Chemical compound N(C(=O)N)C1C(=O)N1 PRZFUMHWRKSAGP-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- FXDAXLSJARZDBW-UHFFFAOYSA-N 6-methylheptyl 2-cyanoprop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C(=C)C#N FXDAXLSJARZDBW-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 241001544353 Barringtonia racemosa Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001438931 Embelia laeta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241000208150 Geraniaceae Species 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241001489138 Haliotis diversicolor Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010054923 Inflammation of wound Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000207844 Scrophulariaceae Species 0.000 description 1
- 240000003377 Shepherdia canadensis Species 0.000 description 1
- 235000018324 Shepherdia canadensis Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- ISQRJFLLIDGZEP-CMWLGVBASA-N Sophoricoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 ISQRJFLLIDGZEP-CMWLGVBASA-N 0.000 description 1
- ISQRJFLLIDGZEP-KJRRRBQDSA-N Sophoricoside Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1 ISQRJFLLIDGZEP-KJRRRBQDSA-N 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- KEIZXGINFPDITQ-UHFFFAOYSA-N UNPD138008 Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 KEIZXGINFPDITQ-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000408907 Xanthoceras Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229920006321 anionic cellulose Polymers 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- QABZOJKEJLITJL-UHFFFAOYSA-N but-3-enoic acid;ethenyl acetate Chemical compound CC(=O)OC=C.OC(=O)CC=C QABZOJKEJLITJL-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- UIDGLYUNOUKLBM-GEBJFKNCSA-N isorhamnetin-3-O-rutinoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)O2)O)=C1 UIDGLYUNOUKLBM-GEBJFKNCSA-N 0.000 description 1
- BGLPQQKZNUKSAR-UHFFFAOYSA-N isorhamnetin-3-O-rutinoside Natural products COc1ccc(cc1O)C2=C(OC3OC(COCC4OC(O)C(O)C(O)C4O)C(O)C(O)C3O)C(=O)c5c(O)cc(O)cc5O2 BGLPQQKZNUKSAR-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940055350 kiwi fruit extract Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 description 1
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 description 1
- IEPKWJCBNGNVDF-UHFFFAOYSA-N narcissin Natural products OC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)=C1 IEPKWJCBNGNVDF-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有高效抗炎止血功能医用胶的制备方法,其特征在于,包括如下重量份数的组分:a‑氰基丙烯酸正辛酯20‑25份、a‑氰基丙烯酸异辛酯25‑35份、聚乙酸乙烯酯2‑6份、高效抗炎组分12‑20份、高效止血组分13‑23份,细胞赋活剂MG‑60 3‑6份,尿囊素8‑10份、水解小麦蛋白1份、稳定剂1份、复合抗炎果油组分150‑220份、无菌水200份。本发明的医用胶特别选用了多种具有抗炎止血功能的提取物并添加了两大高效抗炎组分以及一个高效止血组分以提高整体的抗炎止血的效果,且粘结强度高、止血时间短,符合临床对医用粘合剂的应用要求。
Description
技术领域
本发明属于医用材料技术领域,具体涉及一种具有高效抗炎止血功能医用胶的制备方法。
背景技术
随着医学的进步,临床上对手术技术和辅助材料效果的要求越来越高。现代医学的要求要最大限度地减少病人的痛苦以及给患者最大限度的生命保证,因此手术过程中的快速的止血消炎是尤为重要的。医用粘合剂是医用高分子的一个分支,它以生物组织为粘合对象,人体绝大部分组织、器官在治疗过程中都可以应用粘合技术取代部分缝合,结扎操作,不必麻醉;伤口愈合后自动脱落。与传统方法相比,医用粘合剂的使用可有效缩短手术时间,降低患者疼痛感,可以实现快速止血消炎并且可以快速修复伤口,保证美观。
目前医用粘合剂的主要研究方向在于提高各种粘合剂的粘结强度,然而在目前外科手术中应用的生物医用材料很少具备高效抗炎以及大面积创伤止血的作用。在手术中首先快速完成止血,才能更好的传递药物;具有很好的抗炎效果患者才会更加安全且更早的进入恢复状态。氰基丙烯酸酯医用胶储存、使用过程中甲醛的产生对生物体组织产生副作用,并且随着甲醛浓度的增大对生物体的损伤增加,严重影响了医用粘合剂的效果及应用。
发明内容
基于以上现有技术,本发明的目的在于提供一种结合多种有效组分大大提高止血率以及抗炎效果,同时有效抑制甲醛产生的具有高效抗炎止血功能的医用胶及其制备方法。
本发明的目的是通过以下技术方案实现的:
一种具有高效抗炎止血功能的医用胶,其特征在于,包括如下重量份数的组分:a-氰基丙烯酸正辛酯20-25份、a-氰基丙烯酸异辛酯25-35份、聚乙酸乙烯酯2-6份、高效抗炎组分12-20份、高效止血组分13-23份,细胞赋活剂MG-60 3-6份,尿囊素8-10份、水解小麦蛋白1份、稳定剂1份、复合抗炎果油组分150-220份、无菌水200份;
所述的高效抗炎组分按照重量分数计算,包括鲍鱼抗炎肽2份、云南松毛虫蛹甲壳素3份、玄参多糖6份、文冠果提取物5份;
所述的高效止血组分按照重量分数计算,包括紫地榆提取物5份、新疆紫草提取物3份、薯茛提取物3份、藕节炭提取物6、槐花制炭提取物6份;
所述的复合抗炎果油组分,按照重量分数计算,包括猕猴桃籽油4份、美藤果油3份、杜仲籽油2份和五味子油5份。
进一步,所述稳定剂是由聚阴离子纤维素和2,6-二叔丁基-4-甲基苯酚按照重量份数10:1组合而成。
进一步,所述高效止血组分中的紫地榆提取物为紫地榆乙酸乙酯提取物;所述的新疆紫草提取物为新疆紫草的乙酸乙酯提取物;所述的藕节炭提取物为藕节炭的乙酸乙酯提取物;所述的槐花制炭提取物为槐花制炭的乙酸乙酯提取物,所述的薯茛提取物为薯茛的乙醇提取物。
进一步,所述薯茛提取物的制备是以80%的乙醇水溶液为溶剂,料液比为2:1,于70℃的热水中水浴浸提3h,放暗处静置15h,过滤、旋转蒸发浓缩至1.5g/ml,浓缩液经微孔滤膜器除菌,然后再500℃条件下鼓风干燥制得。
进一步,所述的文冠果提取物的制备方法如下:用流动水冲去文冠果表而泥沙,将臭氧发生器通入无菌水中再次清洗文冠果,将果肉粉碎打成果浆之后,按果浆体积为30%添加去离子水,同时添加果胶酶2.5%,搅拌混匀后在33℃条件下静置50 min;将静置后的上层清液加入90%乙醇溶液,在水温35℃,超声功率100W条件下,超声提取20min,在4000rpm/min转速下离心10 min;将离心所得上层清液浓缩至半流动浆状物后,将浆状物以1:12体积比溶于去离子水中,经搅拌、摇匀、经微孔滤膜器除菌后,得文冠果提取物。
进一步,所述的云南松毛虫蛹甲壳素的提取方法具体操作如下:
(1)脱蛋白和脂类;先将松毛虫蛹装入纱布袋,浸于水中压榨,然后水洗、过滤,分离蛋白等蛹皮内含物和蛹皮,最后将蛹皮置于氢氧化钠溶液中加热,丢弃废碱液后,水洗至中性、晒干;
(2)脱矿物质;将步骤1中己经脱蛋白、脂类的蛹皮置于盐酸溶液中加热处理,丢弃废酸液后,水洗至中性、晒干;
(3)脱色水洗;用过氧化氢处理步骤2所得到的产物,脱色后水洗至中性,晒干即得到甲壳质;
(4)脱乙酰基;将步骤3所得产物置于氢氧化钠溶液中加热,丢弃废碱液,水洗至中性,即得到云南松毛虫蛹甲壳素;
其中,所述氢氧化钠溶液质量分数为8%,浸泡时间为2h,浸泡温度为80℃;盐酸溶液质量分数2.5%,浸泡时间20h,浸泡温度30℃;过氧化氢溶液质量分数11%,浸泡时间2.5h,浸泡温度80℃。
一种具有高效抗炎止血功能的医用胶的制备方法,其特征在于,包括以下步骤:
步骤一,将细胞赋活剂MG-60、尿囊素、水解小麦蛋白、稳定剂按照份数比例加入无菌水中,加热至85℃,搅拌溶解180min,冷却至室温,得到水溶液A;
步骤二,将a-氰基丙烯酸正辛酯、a-氰基丙烯酸异辛酯、聚乙酸乙烯酯按照份数比例于复合抗炎果油组分中,加热至70℃搅拌80min,冷却至室温,得到复合抗炎果油组分溶液B;
步骤三,将上述水溶液A和复合抗炎果油组分溶液B混合均匀,并按照份数比例加入高效抗炎组分和高效止血组分,搅拌4h;
步骤四,将步骤三所得产物经过滤灭菌处理,分装、密封、包装即得具有高效抗炎止血功能的医用胶。
α-氰基丙烯酸酯类医用胶之所以发展迅速是由于它具有一系列独特的优点,即单组分、无溶剂、不需要外加的催化剂等,在常温下即可快速粘合。而且粘接范围广、强度高、具有瞬间固化的特点,更重要的是该类医用胶对皮肤等生物体基本无毒副作用。化学结构的特殊性决定了它在粘接方面的优良性质,α-氰基丙烯酸酯类化合物的分子结构CNCH2CCOOR中α-碳原子吸引电子的能力极强,当接触到极微量的阴离子就会立即发生化学反应。组成生物体的基础物质蛋白质氨基酸链上有大量呈电负性的基团-NH2和-COOH,当接触到α-氰基丙烯酸酯时可迅速发生反应,该原理也使得医用胶广泛应用于临床。α-氰基丙烯酸酯对于组织的影响与烷基的种类和大小有很大关系。一般情况下酯基碳链越长,聚合反应速率越慢,对组织的刺激性减小,胶层柔韧性变好。本发明选用a-氰基丙烯酸正辛酯和a-氰基丙烯酸异辛酯作为体系中的主要原料,其本身具备良好的生物相容性和优异的高效抗炎止血性能。替代针缝手术,使皮肤切口吻合后不留痕迹。聚乙酸乙烯酯(polyvinylacetate),又名聚醋酸乙烯酯。是乙酸乙烯酯(醋酸乙烯酯)的聚合物。英文缩写为PVAc。简称PVAc,醋酸乙烯酯经聚合生成的聚合物。其本身就是优异的胶黏剂,加入到α-氰基丙烯酸酯类基体中可以有效地改善胶黏剂的各种综合性能。
甲壳素是地球上存量极为丰富的一种自然资源,也是自然界中迄今为止被发现的唯一带正电荷的动物纤维素。由于它的分子结构中带有不饱和的阳离子基团,因而对带负电荷的各类有害物质具有强大的吸附作用。同样它也能清除人体内的“垃圾”,达到预防疾病、延年益寿的目的。由于甲壳素具有这种独特功能,它被欧美科学家誉为和蛋白质、脂肪、糖类、维生素、矿物质同等重要的人体第六生命要素。甲壳质又名几丁质、甲壳素、壳多糖,一种聚乙酰氨基葡萄糖的生物高分子聚合物,广泛存在于无脊椎动物的外壳和真菌的菌丝体以及原生动物和某些绿藻中。甲壳质具有抗癌抑制癌、瘤细胞转移,提高人体免疫力及护肝解毒作用,有良好的扼制微生物/细菌/霉菌的作用,同时甲壳素能够消炎并促进创面愈合。溶解后的几丁聚糖呈凝胶状态,具有较强的吸附能力,因甲壳质分子中含有羟基、氨基等极性基团,吸湿性很强,其也是皮肤修复后良好的保湿剂。松毛虫是我国历史性的森林害虫,云南松毛虫是全国危害最严的6大松毛虫之一。在松毛虫资源化的研究中发现,云南松毛虫蛹和成虫中除含有丰富的蛋白质和脂肪外,甲壳素的含量也较高。
血液凝固是一系列酶促过程,最后使纤维蛋白原变为纤维蛋白,血液由溶胶状态转为凝胶状态,凝血酶在凝血中也发挥了重要的作用。血小板在血液凝固过程中发挥着重要作用,它的黏附、聚集、释放起到比血作用,同时它还为各种凝血酶原的活化提供必需的膜磷脂。新疆紫草的化学成分中主要有蒽醌类,酚酸类、生物碱类、苯酚及苯醌类、三萜类及甾醇类、黄酮类以及多糖类等物质。新疆紫草醋酸乙酯提取物具有高效的止血作用,这种止血作用是通过增加纤维蛋白原含量,促进纤维蛋白原转变为纤维蛋白的过程。升高血小板数量,影响抗凝和纤溶系统起作用,而对外源和内源性凝血因子无影响。
紫地榆(Ceruuium .strictipe.s R. Knuth) 牻牛儿苗科老鹤草属植物紫地榆,以根入药,民间又称隔山消,在云南中甸、水宁、水胜、人理等地区广泛分布。长期以来在云南的白族、彝族等地用于治疗肠炎等疾病。研究发现,紫地榆乙醇提取物在体外对常见肠道感染性细菌有显著的抗菌作用,同时紫地榆的抗炎,止血、凝血作用很强,高剂量紫地榆提取物止血效果优于云南自药。本发明选用紫地榆提取物同时兼具了抗炎和快速止血凝血的作用。
藕节为睡莲科植物莲的干燥根茎部。始载于《本经》,列为上品。藕节炭系藕节的炒炭品,收载于例版《中国药典》一部及《全国中药炮制规范》。具有止血、散瘀的功能。藕节炭为睡莲科植物莲的根茎节部。秋、冬二季采挖根茎(藕),切取节部,洗净,晒干,除去须根。藕节呈圆柱形,长2至4厘米,直径约2厘米。表面灰黄色或灰棕色,节部膨大,有多数须根或根痕,两端残留面有裂纹,体轻而质硬,不易折断,横断面有较大的圆孔7至9个,大小不等,气无,味甘,涩。藕节炭提取物甘涩性平,即能收敛止血,又能散瘀血,具有止血不留瘀之特点。
薯茛分布于中国大陆的广东、湖南、广西等地,生长于海拔400米至750米的地区,常生于山坡灌丛或疏林中,目前尚未由人工引种栽培。别名赭魁、薯良、鸡血莲、血母、朱砂七、红药子、金花果、红孩儿、孩儿血、牛血莲、染布薯。薯茛的乙醇提取物有良好的止血和凝血的效果,薯茛提取物中的主要成分为鞣质和甙类。使创伤后渗出物中蛋白质凝固,形成结痂膜,致减少分泌和防止感染,并能使创而的微血管收缩,有局部止血作用,可外用于创伤,因而具有快速高效特点。薯茛提取物中除了上述两种物质之外还含有生物碱类、萜类、甾醇、酚类、黄酮类、醌类化合物,从而综合作用提高的止血效率。
血小板的主要功能是凝血和止血,修补破损的血管。当人体受伤流血时,血小板受到损伤部位激活因素刺激出现血小板的聚集,成为血小板凝块,起到初级止血作用,血小板和血液中的其他凝血物质钙离子和凝血酶等,在破损的血管壁上聚集成团,形成血栓,堵塞破损的伤口和血管,血小板还能释放肾上腺素,引起血管收缩,促进止血。薯茛的乙醇提取物能有效提高血小板的数量,从而缩短出血时问和凝血时间。正是因为该机理,充分证明了薯茛的乙醇提取物具有良好的止血效果。
槐花具有凉血止血,清肝泻火的作用,为中医常用的止血药。炒炭是中药常用的炮制方法之一。槐花制炭提取物中的主要成分为芦丁和鞣制,槐树皂苷和异鼠李素-3-O-芸香糖其均为起到止血作用的主要成分,能明显缩短出血时间。
生物活性肽是对身体功能或状况具有积极影响且最终可能影响人类健康的特定蛋白片段;其预期由安全、可靠和一致的口服递送系统来提供。肠胃蛋白水解酶帮助在消化之后释放肽,且这些被吸收的组分部分对人来说是生理学上活性的。生物活性肽对抗炎、抗高血压、抗氧化、抗癌、抗菌和抗关节炎方面具有优异的效果。海洋生物拥有具有许多营养和药物活性相关的生理功能的各种生物活性天然组分,所述生理功能例如抗氧化、抗炎、抗癌、抗菌、抗高血压、抗凝、抗心血管疾病等。鲍鱼是海洋腹足动物,它们是亚洲、非洲、澳洲和美洲中大量海上养殖的重要渔业和食物工业资源之一。鲍鱼鲜品可食部分蛋白质24%、脂肪0.44%;干品含蛋白质40%、糖元33.7%、脂肪0.9%以及多种维生素和微量元素,足一种对人体非常有利的高蛋白、低脂肪食物。鲍鱼中含有丰富的蛋白质、氨基酸和对调节机体酸碱平衡、维持神经肌肉的兴奋方面具有重要作用的如钙(Ca)、铁(Fe)、锌(Zn)、硒(Se)、镁(Mg)等矿物质元素。研究表明鲍鱼高蛋白,低脂肪,氨基酸种类齐全、配比合理,含有丰富的维生素E和微量元素,同时鲍鱼肉中如EPA、DHA、牛磺酸以及超氧化物歧化酶等生理活性物质的含量也较为丰富。彭汶铎等的研究表明,杂色鲍中含有全部的必需氨基酸,活性物质牛磺酸含量几乎与游离氨基酸总量持平,“生命的火种”硒(Se)的含量非常的高,并且各族维生素含量均十分丰富,磷脂浓度也较高。从鲍鱼中提取的鲍鱼抗炎肽具有更高的抗炎活性,同时与具备了鲍鱼中的大部分营养物质,对于手术后伤口的止血抗炎以及愈合都有着不容忽视的重要作用。
玄参为玄参科多年生草本植物,具有凉血滋阴,泻火解毒的功能。玄参主要成分为多糖类、生物碱。玄参药用历史悠久,其具有对心血管系统的影响,扩张冠状动脉增加心肌营养性血流量,通过扩张血管降低血压、抗血小板聚集、抗炎抗氧化、抑菌、增强免疫力等作用。
文冠果(Xanthocerassorbifolia Bunge),又名木瓜、文登阁、崖木瓜等,属于无患子科,文冠果属,其干燥茎枝称为文冠木。我国传统医学认为,文冠果的枝干、叶片、果皮、花器等部位都是重要药材,可以提取出具有抗炎、改善记忆、防治心血管疾病。文冠果的活性成分目前主要被分为三大类:一类为三萜类化合物,母核多以齐墩果烷型五环三萜为主,包括齐墩果酸和一系列皂苷类化合物;一类主要为黄酮类,指黄酮醇、二氢黄酮醇和黄烷等类型,包括杨梅树皮苷、槲皮素、双氢杨梅树皮苷、表儿茶精等;另一类是香豆素及甾醇,包括秦皮苷、七叶内酯和文冠木素等。其中的文冠木素能够抑制炎症早期的渗出和水肿,炎症中期白细胞趋化和游走,抑制炎症晚期肉芽肿的形成,有着极好的抗炎效果。
猕猴桃含有丰富的维生素C、A、E以及钾、镁、纤维素之外,还含有其他水果比较少见的营养成分-叶酸、胡萝卜素、钙、黄体素、氨基酸、天然肌醇。维生素C可强化免疫系统,促进伤口愈合和对铁质的吸收;肌醇及氨基酸,可补所消耗的营养;它的低钠高钾的完美比例,可补承受手术的病患所失去的体力。叶酸(folic acid)维生素B复合体之一,相当于蝶酰谷氨酸(pteroylglutamic acid,PGA),是米切尔(H.K.Mitchell,1941)从菠菜叶中提取纯化的,故而命名为叶酸。有促进骨髓中幼细胞成熟的作用,人类如缺乏叶酸可引起巨红细胞性贫血以及白细胞减少症。叶酸是人体在利用糖分和氨基酸时的必要物质,是机体细胞生长和繁殖所必需的物质。在体内叶酸以四氢叶酸的形式起作用,四氢叶酸在体内参与嘌呤核酸和嘧啶核苷酸的合成和转化。叶酸在制造核酸(核糖核酸、脱氧核糖核酸)上扮演重要的角色。叶酸帮助蛋白质的代谢,并与维生素B12共同促进红细胞的生成和成熟,是制造红血球不可缺少的物质。叶酸也作为干酪乳杆菌(Lactobacillus casei)及其它微生物的促进增殖因子而起作用。因此猕猴桃提取物可以更有效的帮助和促进伤口的愈合以及高速修复,并且猕猴桃籽油中亚麻酸的含量高达67.34%。
美藤果油是以大戟科植物南美油藤的种子为原料,压榨制得的淡黄色透明油状液体。南美油藤原生长在海拔80-1700m的南美洲安第斯山脉地区热带雨林,在秘鲁、厄瓜多尔等地区己被当地土著人食用了上千年,2006年引种至中国。美藤果油富含不饱和脂肪酸、脂溶性维生素、微量元素等,有辅助降血脂、抗氧化、抗炎等作用。美藤果油含有抑制炎症细胞因子,有着极其良好的抗炎效果。
杜仲(学名Eucommiaulmoides Oliver)又名胶木,为杜仲科植物。杜仲游离氨基酸极少,含有的少量蛋白质,是和绝大多数食品类似的完全蛋白,即能够水解检出对人体必需的8种氨基酸。测定了杜仲所含的15种矿物元素,其中有锌、铜、铁等微量元素,及钙、磷、钾、镁等宏量元素。杜仲籽油中亚麻酸的含量高达62.95%。
五味子(学名:Schisandrachinensis (Turcz.)Baill)为木兰科植物五味子或华中五味子SchisandrasphenantheraRehd. et Wils.的干燥成熟果实。前者习称“北五味子”,后者习称“南五味子”。 秋季果实成熟时采摘,晒干或蒸后晒干,除去果梗及杂质。唐等《新修本草》载“五味皮肉甘酸,核中辛苦,都有咸味”,故有五味子之名。五味子分为南、北二种。古医书称它荎蕏、玄及、会及,最早列于神农本草经上品中药,能滋补强壮之力,药用价值极高,有强身健体之效。其果含有五味子素(Schisandrin C23H3206)及维生素C、树脂、鞣质及少量糖类。有敛肺止咳、滋补涩精、止泻止汗之效。其叶、果实可提取芳香油,种仁含有脂肪油。其中,五味子油籽油中的亚油酸含量可以高达93.30%。
猕猴桃籽油、五味子籽油、美藤果油以及杜仲籽油均含有大量的多烯酸,多烯酸植物油具有极好的辅助降血脂功能、抗氧化功能、抗衰老功能以及抗炎功能。其中关于抗炎功能,Ω-3多烯酸可通过与花生四烯酸竞争代谢,参与炎症的消退与组织修复,影响细胞核因子途径,改变脂筏途径等机制而达到抗炎的作用。亚油酸和亚油酸甲酯能降低炎症相关因子白细胞介素、肿瘤坏死因子和一氧化氮水平,对急、慢性炎症均有明显的改善作用。因此本发明的复合抗炎果油组分结合了四种多烯酸含量极其高的果油组分,充分发挥其抗炎的功效,同时又可以利用果油中的其他营养成分为愈合肌肤提供充足的养分,抗炎的同时加速愈合以及创面的修复。
细胞赋活剂MG-60是海藻糖苷加水淀粉分解物混合溶液,主要功能是细胞赋活作用;避免细胞干燥的保护作用;由于紫外线照射细胞将会受到损伤,通过添加MG-60,受损程度得到减轻;MG-60抑制了炎症性细胞活素之一TNF-a的产生,具有良好的抗炎作用。
小麦作为一种重要的农产品,主要种植于我国中北部地区,长期以来,小麦多用于而粉生产。蛋白质是小麦粉中的第二大组分,水解小麦蛋白:小麦的主要氨基酸麦醇溶蛋白(gl5ad55)和麦谷的蛋白,含有丰富的胱氨酸(cyst55e)是一种含硫氨基酸。它具有保湿、抗氧化作用及柔软细化皮肤,有特别润肤成分,能够有效的改善皮肤状态。同时,水解小麦蛋白为机体合成代谢提供必需的氨基酸,以维持体内氮的平衡。尤其特别适用于抗炎以及外科手术后的蛋白质补充。也就是说,水解小麦蛋白可以同时起到补充蛋白营养、帮助皮肤修复以及抗炎的作用。
尿囊素,别名5-尿基乙内酰胺、脲基醋酸内酰胺、脲基海因、脲咪唑二酮,是一种乙内酰脲衍生物。目前世界上尿囊素的年生产能力约5万吨,需求市场主要是医药、化妆品和农业三大领域,由于传统工艺从天然动植物中提取天然尿囊素的含量很低、工艺复杂、成本太高,无法大规模运用。在医药方面,尿囊素具有促进细胞生长,加快伤口愈合,软化角质蛋白等生理功能,是皮肤创伤的良好愈合剂和抗溃疡药剂。另外,尿囊素可用作缓解和治疗皮肤干燥症、皮肤溃疡,同时对于炎症有较好疗效。由于尿囊素是一种两性化合物,能结合多种物质形成复盐,具有避光、杀菌防腐、止痛、抗氧化作用,能使皮肤保持水份,更加滋润和柔软。
天然纤维素是自然界中分布最广、含量最多的多糖,来源十分丰富。当前纤维素的改性技术主要集中在醚化和酯化两方面。羧甲基化反应是醚化技术的一种。纤维素经羧甲基化后得到羧甲基纤维素(CMC),其水溶液具有增稠、成膜、黏接、水分保持、胶体保护等作用。羧甲基纤维素(CMC)的高端替代产品为聚阴离子纤维素(PAC)亦是一种阴离子型纤维素醚,具有更高的取代度和取代均匀度,分子链较短,分子结构更趋稳定,因此具有更好的综合性能,溶解性亦增强。应用于羧甲基纤维素可应用的所有行业,可提供更好的稳定性能和满足更高的工艺要求。2,6-二叔丁基-4-甲基苯酚,通俗来说,即是能防止聚合物材料因氧化引起变质的物质,是一种有效的用于医疗用品的稳定剂。聚阴离子纤维素(PAC)和2,6-二叔丁基-4-甲基苯酚这两种物质的联合使用可以有效的为反应系统提供更好的稳定性,提高耐磨性等综合性能,同时可以增强医用胶的粘合性能并具有水分保持性能。
由于采用了以上技术方案,本发明具有如下有益效果:
1、本发明高效抗炎止血组分选用的高效抗炎组分包括鲍鱼抗炎肽、云南松毛虫蛹甲壳素、玄参多糖、文冠果提取物,利用四种具有截然不同的抗炎原理和功效的组分组成了第一个高效抗炎体系。其中,充分结合了海洋生活抗炎活性的鲍鱼抗炎肽,能够消炎并促进创面愈合的天然高效的云南松毛虫蛹甲壳素,抗血小板聚集、抗炎抗氧化的药用历史就悠久的玄参多糖以及含有文冠木素能够抑制炎症早期的渗出和水肿,炎症中期白细胞趋化和游走,抑制炎症晚期肉芽肿的形成,有着极好的抗炎效果的文冠果提取物,四种主要抗炎成分协同互助才奠定了本发明产品高效的抗炎性能。再结合复合抗炎果油组分形成的复合果油抗炎体系。两大抗炎体系有效成分相辅相成,再加上高效止血组分的缩短出血时间和凝血时间的快速止血效果相互协同从而有效的实现了本发明高效抗炎止血的目的。
2、本发明新疆紫草乙酸乙酯提取物具有高效的止血作用,这种止血作用是通过增加纤维蛋白原含量,促进纤维蛋白原转变为纤维蛋白的过程。升高血小板数量,影响抗凝和纤溶系统起作用,而对外源和内源性凝血因子无影响。薯茛的乙醇提取物能有效提高血小板的数量,从而缩短出血时问和凝血时间。槐树皂苷和异鼠李素-3-O-芸香糖其均为起到止血作用的主要成分,能明显缩短出血时间。藕节炭提取物甘涩性平,即能收敛止血,又能散瘀血,具有止血不留瘀之特点。
紫地榆的抗炎,止血、凝血作用很强,高剂量紫地榆提取物止血效果优于云南自药,本发明选用紫地榆提取物同时兼具了抗炎和快速止血凝血的作用。本发明充分结合了高效止血组分中五种物质的不同的止血特效,构建了快速高效的止血体系,用以结合两大抗炎体系共同实现高效抗炎止血的目的。
3、本发明具有高效抗炎止血功能的医用胶选用的复合抗炎果油,由猕猴桃籽油、五味子籽油、美藤果油以及杜仲籽油协同使用,通过四种具有抗炎功效的果油组成的一个基础而强大的果油抗炎体系。猕猴桃籽油、五味子籽油、美藤果油以及杜仲籽油均含有大量的多烯酸,多烯酸植物油具有极好的辅助降血脂功能、抗氧化功能、抗衰老功能以及抗炎功能。其中关于抗炎功能,Ω-3多烯酸可通过与花生四烯酸竞争代谢,参与炎症的消退与组织修复,影响细胞核因子途径,改变脂筏途径等机制而达到抗炎的作用。亚油酸和亚油酸甲酯能降低炎症相关因子白细胞介素、肿瘤坏死因子和一氧化氮水平,对急、慢性炎症均有明显的改善作用。因此本发明的复合抗炎果油组分结合了四种多烯酸含量极其高的果油组分,充分发挥其抗炎的功效,同时又可以利用果油中的其他营养成分为愈合肌肤提供充足的养分,抗炎的同时加速愈合以及创面的修复。
4、本发明具有高效抗炎止血功能的医用胶特别添加了尿囊素,其有着其独特而重要的作用。尿囊素具有促进细胞生长,加快伤口愈合,软化角质蛋白等生理功能,是皮肤创伤的良好愈合剂。另外,尿囊素可用作缓解和治疗皮肤干燥症、皮肤溃疡,同时对于炎症有较好疗效。由于尿囊素是一种两性化合物,能结合多种物质形成复盐,具有避光、杀菌防腐、止痛、抗氧化作用,能使皮肤保持水份,更加滋润和柔软。尿囊素的使用,同时还相当于在体系中充当了甲醛抑制剂,有效的起到甲醛抑制剂的作用,因此本体系无需额外添加单独的甲醛抑制剂以及防腐剂。
5、本发明具有高效抗炎止血功能的医用胶选用的除了稳定剂以外的每一种添加成分均具有一定的抗炎止血功能,包括细胞赋活剂MG-60、小麦水解蛋白、尿囊素等均成为了整个高效抗炎止血产品必不可少的一个组成部分,多种高效抗炎止血组分的功效浑然天成,制备得到本发明具有高效抗炎止血功能的医用胶。
本发明具有高效抗炎止血功能的医用胶的粘结强度均大于60N,对伤口的止血时间低于110秒,整体治愈率较高,生物相容性高,对伤口组织无刺激,降低致敏率,综合性能优秀,符合临床对医用粘合剂的应用要求,通过提高医用粘合剂的高效抗炎止血性能最大限度的降低患者的需要承受的痛苦。
具体实施方式
下面通过具体实施例对本发明进行具体的描述:
实施例1
一种具有高效抗炎止血功能的医用胶,包括如下重量份数的组分:a-氰基丙烯酸正辛酯20份、a-氰基丙烯酸异辛酯25份、聚乙酸乙烯酯2份、高效抗炎组分12份、高效止血组分13份,细胞赋活剂MG-60 3份,尿囊素8份、水解小麦蛋白1份、稳定剂1份、复合抗炎果油组分150份、无菌水200份;高效抗炎组分按照重量分数计算,包括鲍鱼抗炎肽2份、云南松毛虫蛹甲壳素3份、玄参多糖6份、文冠果提取物5份;高效止血组分按照重量分数计算,包括紫地榆提取物5份、新疆紫草提取物3份、薯茛提取物3份、藕节炭提取物6、槐花制炭提取物6份;复合抗炎果油组分,按照重量分数计算,包括猕猴桃籽油4份、美藤果油3份、杜仲籽油2份和五味子油5份。稳定剂是由聚阴离子纤维素和2,6-二叔丁基-4-甲基苯酚按照重量份数10:1组合而成。高效止血组分中的紫地榆提取物为紫地榆乙酸乙酯提取物;新疆紫草提取物为新疆紫草的乙酸乙酯提取物;藕节炭提取物为藕节炭的乙酸乙酯提取物;槐花制炭提取物为槐花制炭的乙酸乙酯提取物,薯茛提取物为薯茛的乙醇提取物。
采用上述实施例制备医用粘合剂对伤口进行涂抹,并进行相关性能测试,其测试结果为:本发明具有高效抗炎止血功能的医用胶的粘结强度为61N,对伤口的止血时间为109秒,整体治愈率较高。
实施例2
一种具有高效抗炎止血功能的医用胶,包括如下重量份数的组分: a-氰基丙烯酸正辛酯22份、a-氰基丙烯酸异辛酯28份、聚乙酸乙烯酯4份、高效抗炎组分16份、高效止血组分18份,细胞赋活剂MG-60 4份,尿囊素9份、水解小麦蛋白1份、稳定剂1份、复合抗炎果油组分180份、无菌水200份;高效抗炎组分按照重量分数计算,包括鲍鱼抗炎肽2份、云南松毛虫蛹甲壳素3份、玄参多糖6份、文冠果提取物5份;高效止血组分按照重量分数计算,包括紫地榆提取物5份、新疆紫草提取物3份、薯茛提取物3份、藕节炭提取物6、槐花制炭提取物6份;复合抗炎果油组分,按照重量分数计算,包括猕猴桃籽油4份、美藤果油3份、杜仲籽油2份和五味子油5份。稳定剂是由聚阴离子纤维素和2,6-二叔丁基-4-甲基苯酚按照重量份数10:1组合而成。高效止血组分中的紫地榆提取物为紫地榆乙酸乙酯提取物;新疆紫草提取物为新疆紫草的乙酸乙酯提取物;藕节炭提取物为藕节炭的乙酸乙酯提取物;槐花制炭提取物为槐花制炭的乙酸乙酯提取物,薯茛提取物为薯茛的乙醇提取物。
采用上述实施例制备医用粘合剂对伤口进行涂抹,并进行相关性能测试,其测试结果为:本发明具有高效抗炎止血功能的医用胶的粘结强度为62N,对伤口的止血时间为106秒,整体治愈率较高。
实施例3
一种具有高效抗炎止血功能的医用胶,包括如下重量份数的组分: a-氰基丙烯酸正辛酯24份、a-氰基丙烯酸异辛酯32份、聚乙酸乙烯酯5份、高效抗炎组分18份、高效止血组分20份,细胞赋活剂MG-60 5份,尿囊素10份、水解小麦蛋白1份、稳定剂1份、复合抗炎果油组分200份、无菌水200份;高效抗炎组分按照重量分数计算,包括鲍鱼抗炎肽2份、云南松毛虫蛹甲壳素3份、玄参多糖6份、文冠果提取物5份;高效止血组分按照重量分数计算,包括紫地榆提取物5份、新疆紫草提取物3份、薯茛提取物3份、藕节炭提取物6、槐花制炭提取物6份;复合抗炎果油组分,按照重量分数计算,包括猕猴桃籽油4份、美藤果油3份、杜仲籽油2份和五味子油5份。稳定剂是由聚阴离子纤维素和2,6-二叔丁基-4-甲基苯酚按照重量份数10:1组合而成。高效止血组分中的紫地榆提取物为紫地榆乙酸乙酯提取物;新疆紫草提取物为新疆紫草的乙酸乙酯提取物;藕节炭提取物为藕节炭的乙酸乙酯提取物;槐花制炭提取物为槐花制炭的乙酸乙酯提取物,薯茛提取物为薯茛的乙醇提取物。
采用上述实施例制备医用粘合剂对伤口进行涂抹,并进行相关性能测试,其测试结果为:本发明具有高效抗炎止血功能的医用胶的粘结强度为61.5N,对伤口的止血时间为107秒,整体治愈率较高。
实施例4
一种具有高效抗炎止血功能的医用胶,包括如下重量份数的组分: a-氰基丙烯酸正辛酯25份、a-氰基丙烯酸异辛酯35份、聚乙酸乙烯酯6份、高效抗炎组分20份、高效止血组分23份,细胞赋活剂MG-60 6份,尿囊素10份、水解小麦蛋白1份、稳定剂1份、复合抗炎果油组分220份、无菌水200份;高效抗炎组分按照重量分数计算,包括鲍鱼抗炎肽2份、云南松毛虫蛹甲壳素3份、玄参多糖6份、文冠果提取物5份;高效止血组分按照重量分数计算,包括紫地榆提取物5份、新疆紫草提取物3份、薯茛提取物3份、藕节炭提取物6、槐花制炭提取物6份;复合抗炎果油组分,按照重量分数计算,包括猕猴桃籽油4份、美藤果油3份、杜仲籽油2份和五味子油5份。稳定剂是由聚阴离子纤维素和2,6-二叔丁基-4-甲基苯酚按照重量份数10:1组合而成。高效止血组分中的紫地榆提取物为紫地榆乙酸乙酯提取物;新疆紫草提取物为新疆紫草的乙酸乙酯提取物;藕节炭提取物为藕节炭的乙酸乙酯提取物;槐花制炭提取物为槐花制炭的乙酸乙酯提取物,薯茛提取物为薯茛的乙醇提取物。
采用上述实施例制备医用粘合剂对伤口进行涂抹,并进行相关性能测试,其测试结果为:本发明具有高效抗炎止血功能的医用胶的粘结强度为62N,对伤口的止血时间为105秒,整体治愈率较高。
上述各个实施例中
新疆紫草提取物的制备方法如下:
将新疆紫草经干燥、打粉后过100目筛,得到新疆紫草的粉状物,然后加入95%乙醇溶液,在水温45℃,超声功率200W条件下,超声提取35min,得提取液;将提取液过滤减压浓缩,得浆状物;将浆状物以1:15体积比溶于去离子水中,经搅拌、摇匀、经微孔滤膜器除菌后,得到新疆紫草提取物。
薯茛提取物的制备方法如下:
薯茛提取物的制备是以80%的乙醇水溶液为溶剂,料液比为2:1,于70℃的热水中水浴浸提3h,放暗处静置15h,过滤、旋转蒸发浓缩至1.5g/ml,浓缩液经微孔滤膜器除菌,然后再500℃条件下鼓风干燥制得。
文冠果提取物的制备方法如下:
用流动水冲去文冠果表而泥沙,将臭氧发生器通入无菌水中再次清洗文冠果,将果肉粉碎打成果浆之后,按果浆体积为30%添加去离子水,同时添加果胶酶2.5%,搅拌混匀后在33℃条件下静置50 min;将静置后的上层清液加入90%乙醇溶液,在水温35℃,超声功率100W条件下,超声提取20min,在4000rpm/min转速下离心10 min;将离心所得上层清液浓缩至半流动浆状物后,将浆状物以1:12体积比溶于去离子水中,经搅拌、摇匀、经微孔滤膜器除菌后,得文冠果提取物。
云南松毛虫蛹甲壳素的提取方法具体操作如下:
(1)脱蛋白和脂类;先将松毛虫蛹装入纱布袋,浸于水中压榨,然后水洗、过滤,分离蛋白等蛹皮内含物和蛹皮,最后将蛹皮置于氢氧化钠溶液中加热,丢弃废碱液后,水洗至中性、晒干;
(2)脱矿物质;将步骤1中己经脱蛋白、脂类的蛹皮置于盐酸溶液中加热处理,丢弃废酸液后,水洗至中性、晒干;
(3)脱色水洗;用过氧化氢处理步骤2所得到的产物,脱色后水洗至中性,晒干即得到甲壳质;
(4)脱乙酰基;将步骤3所得产物置于氢氧化钠溶液中加热,丢弃废碱液,水洗至中性,即得到云南松毛虫蛹甲壳素;
其中,所述氢氧化钠溶液质量分数为8%,浸泡时间为2h,浸泡温度为80℃;盐酸溶液质量分数2.5%,浸泡时间20h,浸泡温度30℃;过氧化氢溶液质量分数11%,浸泡时间2.5h,浸泡温度80℃。
上述具有高效抗炎止血功能的医用胶的制备方法,包括以下步骤:
步骤一,将细胞赋活剂MG-60、尿囊素、水解小麦蛋白、稳定剂按照份数比例加入无菌水中,加热至85℃,搅拌溶解180min,冷却至室温,得到水溶液A;
步骤二,将a-氰基丙烯酸正辛酯、a-氰基丙烯酸异辛酯、聚乙酸乙烯酯按照份数比例于复合抗炎果油组分中,加热至70℃搅拌80min,冷却至室温,得到复合抗炎果油组分溶液B;
步骤三,将上述水溶液A和复合抗炎果油组分溶液B混合均匀,并按照份数比例加入高效抗炎组分和高效止血组分,搅拌4h;
步骤四,将步骤三所得产物经过滤灭菌处理,分装、密封、包装即得具有高效抗炎止血功能的医用胶。
性能测试
采用上述实施例制备医用粘合剂对伤口进行涂抹,本发明具有高效抗炎止血功能的医用胶的粘结强度均大于60N,对伤口的止血时间为低于110秒,整体治愈率较高,生物相容性高,对伤口组织无刺激,降低致敏率,综合性能优秀,符合临床对医用粘合剂的应用要求。
以上所述仅为本发明的实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书内容所作的等效结构或等效流程变换,或直接或间接运用在其他相关的技术领域,均同理包括在本发明的专利保护范围内。
Claims (1)
1.一种具有高效抗炎止血功能医用胶的制备方法,所述具有高效抗炎止血功能的医用胶,包括如下重量份数的组分:a-氰基丙烯酸正辛酯20-25份、a-氰基丙烯酸异辛酯25-35份、聚乙酸乙烯酯2-6份、高效抗炎组分12-20份、高效止血组分13-23份,细胞赋活剂MG-603-6份,尿囊素8-10份、水解小麦蛋白1份、稳定剂1份、复合抗炎果油组分150-220份、无菌水200份;
所述稳定剂是由聚阴离子纤维素和2,6-二叔丁基-4-甲基苯酚按照重量份数10:1组合而成;
所述的高效抗炎组分按照重量分数计算,包括鲍鱼抗炎肽2份、云南松毛虫蛹甲壳素3份、玄参多糖6份、文冠果提取物5份;
所述的高效止血组分按照重量分数计算,包括紫地榆提取物5份、新疆紫草提取物3份、薯茛提取物3份、藕节炭提取物6、槐花制炭提取物6份;
所述高效止血组分中的紫地榆提取物为紫地榆乙酸乙酯提取物;所述的新疆紫草提取物为新疆紫草的乙酸乙酯提取物;所述的藕节炭提取物为藕节炭的乙酸乙酯提取物;所述的槐花制炭提取物为槐花制炭的乙酸乙酯提取物,所述的薯茛提取物为薯茛的乙醇提取物;
所述的复合抗炎果油组分,按照重量分数计算,包括猕猴桃籽油4份、美藤果油3份、杜仲籽油2份和五味子油5份;
所述制备方法包括以下步骤:
步骤一,将细胞赋活剂MG-60、尿囊素、水解小麦蛋白、稳定剂按照份数比例加入无菌水中,加热至85℃,搅拌溶解180min,冷却至室温,得到水溶液A;
步骤二,将a-氰基丙烯酸正辛酯、a-氰基丙烯酸异辛酯、聚乙酸乙烯酯按照份数比例于复合抗炎果油组分中,加热至70℃搅拌80min,冷却至室温,得到复合抗炎果油组分溶液B;
步骤三,将上述水溶液A和复合抗炎果油组分溶液B混合均匀,并按照份数比例加入高效抗炎组分和高效止血组分,搅拌4h;
步骤四,将步骤三所得产物经过滤灭菌处理,分装、密封、包装即得具有高效抗炎止血功能的医用胶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810881120.5A CN108939139B (zh) | 2018-08-04 | 2018-08-04 | 一种具有高效抗炎止血功能医用胶的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810881120.5A CN108939139B (zh) | 2018-08-04 | 2018-08-04 | 一种具有高效抗炎止血功能医用胶的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108939139A CN108939139A (zh) | 2018-12-07 |
| CN108939139B true CN108939139B (zh) | 2021-02-02 |
Family
ID=64467797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810881120.5A Active CN108939139B (zh) | 2018-08-04 | 2018-08-04 | 一种具有高效抗炎止血功能医用胶的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108939139B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173261A (zh) * | 2014-08-28 | 2014-12-03 | 皖南医学院 | 一种抗敏舒缓修复肌肤乳液及其制备方法 |
| CN104337703A (zh) * | 2013-08-06 | 2015-02-11 | 赢创工业集团股份有限公司 | 甲硫氨酰基-甲硫氨酸立体异构体及其在化妆品中的用途 |
| CN105154502A (zh) * | 2015-07-31 | 2015-12-16 | 合肥工业大学 | 一种酶法改性小麦蛋白制备肉制品填充剂的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083718B (zh) * | 2011-11-02 | 2015-06-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种可生物降解的医用粘合剂及其制备方法和用途 |
| JP6193067B2 (ja) * | 2012-09-20 | 2017-09-06 | 三洋化成工業株式会社 | 外科用止血材基材及び外科用止血材 |
| CN102925064A (zh) * | 2012-10-25 | 2013-02-13 | 无锡市三力胶带厂 | 一种介入性抗感染水性胶粘剂 |
| CN105078868B (zh) * | 2015-09-18 | 2018-03-27 | 皖南医学院 | 一种美白保湿的祛斑乳液及其制备方法 |
| CN106039391A (zh) * | 2016-06-21 | 2016-10-26 | 林春梅 | 一种抗菌高粘合医用胶水及其制备方法 |
-
2018
- 2018-08-04 CN CN201810881120.5A patent/CN108939139B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104337703A (zh) * | 2013-08-06 | 2015-02-11 | 赢创工业集团股份有限公司 | 甲硫氨酰基-甲硫氨酸立体异构体及其在化妆品中的用途 |
| CN104173261A (zh) * | 2014-08-28 | 2014-12-03 | 皖南医学院 | 一种抗敏舒缓修复肌肤乳液及其制备方法 |
| CN105154502A (zh) * | 2015-07-31 | 2015-12-16 | 合肥工业大学 | 一种酶法改性小麦蛋白制备肉制品填充剂的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108939139A (zh) | 2018-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maan et al. | The therapeutic properties and applications of Aloe vera: A review | |
| US6605296B1 (en) | Natural substances based agent | |
| Kiew et al. | Jewel of the seabed: sea cucumbers as nutritional and drug candidates | |
| KR102376726B1 (ko) | 건강기능성 펫푸드 및 이의 제조방법 | |
| CN101518336A (zh) | 一种具有抗氧化功能的营养食品及其制备方法 | |
| CN103053987B (zh) | 一种南瓜风味颗粒调味料 | |
| Diarra et al. | Potential of Morinda (Morinda citrifolia L.) products as alternative to chemical additives in poultry diets | |
| Kshirsagar et al. | Pomegranate (Punica granatum L): A fruitful fountain of remedial potential | |
| Khutare et al. | A review on various medicinal applications of kiwi fruit | |
| CN110693025B (zh) | 一种多功能成分协同降血糖的组合物及其应用 | |
| KR102042798B1 (ko) | 천연 원료 추출물을 포함하는 기능성 환의 제조방법 | |
| Hassan et al. | Wheat grass (Triticum aestivum L.) benefits health in a pandemic scenario | |
| KR102284645B1 (ko) | 간식용 젤리 및 그 제조방법 | |
| CN108939139B (zh) | 一种具有高效抗炎止血功能医用胶的制备方法 | |
| CN108888801B (zh) | 一种具有高效抗炎止血功能的医用胶 | |
| KR102748901B1 (ko) | 유선증식 및 지방축적을 억제하고, 지방분해 및 체중조절에 도움을 주는 식품 조성물 | |
| CN105029271A (zh) | 一种盐地碱蓬咀嚼片及其制备方法 | |
| CN104223122A (zh) | 金柚膳食纤维及其制备方法 | |
| KR102651344B1 (ko) | 항염, 근육 증강, 관절 건강 및 연골 건강 개선용 식품 조성물 | |
| KR102462469B1 (ko) | 버섯균사체를 이용한 복합발효 분말의 제조방법 | |
| KR102289257B1 (ko) | 갱년기 증상 개선을 위한 식품 조성물 | |
| KR20070038487A (ko) | 뇌혈전,심근경색,당뇨의예방치료의성분을함유하는복합조성물 | |
| CN108635618B (zh) | 一种具有促进愈合以及修复功能医用胶的制备方法 | |
| CN105087284B (zh) | 一种复方树莓养生酒及其制备方法 | |
| CN106561933A (zh) | 一种降血压血脂的金花茶及其制作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ye Shanming Inventor after: Lin Shanguang Inventor after: Ying Lei Inventor before: Lin Shanguang Inventor before: Ye Shanming Inventor before: Li Chenghui Inventor before: Ying Lei |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |